Lates News

According to AI Fast News by Every Economic Daily, Dongwu Securities issued a research report on April 1, giving a "buy" rating to XianlTai (002294.SZ). The reasons for the rating mainly include: 1) the old-fashioned chronic disease leader is innovatively transforming, heavyweight varieties are expected to contribute billions of revenue; 2) the new mechanism BIC molecule, JK07 is expected to overturn the global heart failure market pattern; 3) the first domestically developed ARNI drugs lead the way, and the hypertension product matrix is comprehensively upgraded; 4) Metabolism + Nephrology + Orthopedics advancing together, significant progress and rich pipeline. (Daily Economic News)